Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Arryx was a life sciences technology company that pioneered the commercialization of holographic optical trapping (HOT) systems. The company's technology utilized laser light to create hundreds of independent "optical tweezers," allowing for the simultaneous, non-contact manipulation of microscopic particles and biological cells in three dimensions. Their primary product, the BioRyx 200, was designed for researchers in drug discovery and cell biology to perform complex micro-manipulations and cell sorting. Founded in 2000 as a spin-out from the University of Chicago, Arryx was eventually acquired by Haemonetics Corporation in 2006. The acquisition aimed to integrate Arryx's precision cell-handling capabilities into Haemonetics' blood processing and surgical product lines.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Arryx.